NCT05338541View on ClinicalTrials.gov

Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Neuroblastoma in Children
Interventions
DRUG

Tucidinostat and etoposide

Tucidinostat: 3+3 design，14 mg/m2，17.5 mg/m2，23 mg/m2 etoposide: 50mg/m2,

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Yizhuo Zhang

OTHER